After obtaining his MD at the Medical University of Vienna,Dr.Reiberger did a first postdoc at the Department of Pathophysiology at MedUni Vienna focusing on ex-situliver perfusion and liver cell biology. During his residency for Internal Medicine, Thomas pursued a career as a physician-scientist while conducting translational clinical studies on portal hypertension and fibrosis. In addition to his clinical activity, he established the Vienna Hepatic Experimental (HEPEX) and Clinical Hepatic Hemodynamic Laboratory at MedUni Vienna. The main mission of his HEPEX research team is the exploration of novel treatment options for liver fibrosis and portal hypertension, such as anti-angiogenic drugs, FXR agonists, and modulators of the soluble guanylyl cyclase. In 2011, he received his veniadocendiand in 2012 he obtained his board certification for Internal Medicine. After another postdoctoral fellowship in the United States from 2012 to 2015, Thomas Reiberger joined the faculty at the Division of Gastroenterology and Hepatology at MedUni Vienna. He conducted seminal studies in the field of liver cirrhosis and portal hypertension. Thomas Reiberger is also the director of the Cirrhosis Outpatient Clinic and the Vienna Hepatic Hemodynamic  Laboratory at the Vienna  General Hospital. In his role as the coordinator of the Rare Liver Disease (RALID) Center of the European Reference Network (ERN) RARE-LIVER at the Vienna Medical University Campus, he complements the mission of the LBI-RUD with translational  research  on  rare  liver  diseases.